Anna D. Garrett, PharmD, BCPS, CPP
The FDA recently
announced an update
to the product labeling
for the Ortho-Evra
contraceptive patch.
Information regarding
the risk of developing
venous thromboembolism
has been
changed, based on
increased concerns that the patch
increases the risk of blood clots, compared
with other types of birth control
with similar ingredients. Two recent
studies produced conflicting data
regarding this issue, but the agency
determined that the concerns were
great enough to support the labeling
change.
The majority of women can use the
patch safely. The risk of embolic events,
however, increases significantly with
smoking, high blood pressure, diabetes,
high cholesterol, a family history of clotting
disorders, heart attack, stroke,
chest pain, certain types of cancer,
jaundice, or liver tumors. Women
should consider an alternative method
of birth control if any of these conditions
exist.
Dr. Garrett is a clinical pharmacist practitioner at Cornerstone Health Care in High Point, NC.